European Centre for Disease Prevention and Control, Stockholm, Sweden; University of Pisa, Pisa, Italy.
Pallas Health Research and Consultancy B.V., Rotterdam, the Netherlands.
J Hosp Infect. 2019 Aug;102(4):359-368. doi: 10.1016/j.jhin.2019.03.004. Epub 2019 Mar 15.
In the European Union/European Economic Area (EU/EEA) approximately 9 million people are chronically infected with hepatitis B virus (HBV) or hepatitis C virus (HCV), and many are undiagnosed. Targeted active case finding initiatives are needed. Iatrogenic transmission of HBV/HCV is relevant in Europe but people at risk of infection are often overlooked. This study aimed to identify groups at increased risk of HBV/HCV infection due to iatrogenic transmission, including healthcare workers, and to estimate incidence and prevalence. PubMed and Embase were systematically searched in February 2017 using strings combining terms for HBV/HCV, occurrence and population subgroups. All retrieved publications were screened and included articles were quality assessed. A predefined set of variables were extracted, and detailed summary tables were developed per population group of interest, virus and outcome. Thirty-eight articles were included, two reported on HBV, 22 on HCV and 16 on both, contributing 70 estimates of prevalence or incidence among: haemodialysis recipients, diabetes patients, recipients of substances of human origin, recipients of medical/dental procedures and healthcare workers. Estimates varied widely from 0.4% to 11.7% for HBV and from 0.7% to over 90% for HCV with most being higher than in the general population. Despite the limited number of studies retrieved, mostly old and focused on populations with multiple risk factors, our findings highlight the importance of considering population groups at higher risk for HBV/HCV iatrogenic transmission as target groups for active case finding in the EU/EEA. Test offers should be guided by individual risk assessment alongside local epidemiological data and local context.
在欧盟/欧洲经济区(EU/EEA),约有 900 万人慢性感染乙型肝炎病毒(HBV)或丙型肝炎病毒(HCV),且许多人未被诊断。需要开展有针对性的主动病例发现倡议。HBV/HCV 的医源性传播在欧洲相关,但往往会忽视感染风险人群。本研究旨在确定因医源性传播而感染 HBV/HCV 风险增加的人群,包括医护人员,并估计发病率和患病率。2017 年 2 月,使用包含 HBV/HCV、发生和人群亚组的术语组合,对 PubMed 和 Embase 进行了系统检索。筛选检索到的所有出版物,并对纳入的文章进行了质量评估。提取了一套预定的变量,并针对感兴趣的人群组、病毒和结局,分别制定了详细的汇总表。共纳入 38 篇文章,其中 2 篇报告 HBV,22 篇报告 HCV,16 篇同时报告 HBV 和 HCV,共提供 70 项关于血液透析患者、糖尿病患者、人源物质接受者、医疗/牙科程序接受者和医护人员的 HBV/HCV 患病率或发病率的估计值。HBV 的估计值范围从 0.4%到 11.7%,HCV 的估计值范围从 0.7%到 90%以上,大多数高于普通人群。尽管检索到的研究数量有限,且大多数是针对具有多种危险因素的人群的旧研究,但我们的研究结果强调了将医源性传播风险较高的人群视为欧盟/欧洲经济区主动病例发现的目标人群的重要性。检测建议应根据个体风险评估、当地流行病学数据和当地情况来指导。